Moving IgA Nephropathy Treatment Forward

We are excited to have received accelerated approval for FILSPARI® (sparsentan)  for adults living with IgA nephropathy, and are grateful to the patient community, clinical trial investigators, and all those who worked so hard to reach this milestone.


Learn More


We are driven by science

The science we are advancing in rare kidney and metabolic disease has the potential to set new standards of care and bring hope to people with these rare disorders.

Learn More View Our Pipeline